Skip to main content
. 2023 Jan;64(1):109–116. doi: 10.2967/jnumed.122.263962

FIGURE 6.

FIGURE 6.

Experiment 4. Single treatment 4 d after injection of 106 tumor cells intravenously (8 animals per group) was studied and survival assessed. Groups included controls (no treatment), 10 μg of unlabeled rituximab, 3,700 kBq of 213Bi-rituximab, 2,035 kBq of 131I-tositumomab, and 1,295 kBq of 90Y-rituximab. Cures were common with 213Bi-rituximab and 131I-tositumomab.